JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kharasch, E. D.
Right arrow Articles by Nogami, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kharasch, E. D.
Right arrow Articles by Nogami, W.
Related Collections
Right arrow Anesthetic Techniques
Right arrow Pharmacology
Anesth Analg 2001;93:1511-1520
© 2001 International Anesthesia Research Society


ANESTHETIC PHARMACOLOGY

Long-Duration Low-Flow Sevoflurane and Isoflurane Effects on Postoperative Renal and Hepatic Function

Evan D. Kharasch, MD PhD*{dagger}, Edward J. Frink, Jr., MD{ddagger}, Alan Artru, MD*, Piotr Michalowski, MD PhD*{dagger}, G. Alec Rooke, MD PhD*{dagger}, and Wallace Nogami, MD{ddagger}

*Department of Anesthesiology, University of Washington, Seattle, Washington; {dagger}Anesthesiology Service, Puget Sound Veterans Affairs Healthcare System, Seattle, Washington; {ddagger}Department of Anesthesiology, University of Arizona Medical Center, Tucson, Arizona

Address correspondence and reprint requests to Evan Kharasch, MD, PhD, Department of Anesthesiology, Box 356540, University of Washington, 1959 N.E. Pacific St. RR-442, Seattle, WA 98195. Address e-mail to kharasch{at}u.washington.edu

Sevoflurane degradation by carbon dioxide absorbents during low-flow anesthesia forms the haloalkene Compound A, which causes nephrotoxicity in rats. Numerous studies have shown no effects of Compound A formation on postoperative renal function after moderate-duration (3–4 h) low-flow sevoflurane; however, effects of longer exposures remain unresolved. We compared renal function after long-duration low-flow (<1 L/min) sevoflurane and isoflurane anesthesia in consenting surgical patients with normal renal function. To maximize degradant exposure, Baralyme® was used, and anesthetic concentrations were maximized (no nitrous oxide and minimal opioids). Inspired and expired Compound A concentrations were quantified. Blood and urine were obtained for laboratory evaluation. Sevoflurane (n = 28) and isoflurane (n = 27) groups were similar with respect to age, sex, weight, ASA status, and anesthetic duration (9.1 ± 3.0 and 8.2 ± 3.0 h, mean ± SD) and exposure (9.2 ± 3.6 and 9.1 ± 3.7 minimum alveolar anesthetic concentration hours). Maximum inspired Compound A was 25 ± 9 ppm (range, 6–49 ppm), and exposure (area under the concentration-time curve) was 165 ± 95 (35–428) ppm · h. There was no significant difference between anesthetic groups in 24- or 72-h serum creatinine, blood urea nitrogen, creatinine clearance, or 0- to 24-h or 48- to 72-h urinary protein or glucose excretion. Proteinuria and glucosuria were common in both groups. There was no correlation between Compound A exposure and any renal function measure. There was no difference between anesthetic groups in 24- or 72-h aspartate aminotransferase or alanine aminotransferase. These results show that the renal and hepatic effects of long-duration low-flow sevoflurane and isoflurane were similar. No evidence for low-flow sevoflurane nephrotoxicity was observed, even at high Compound A exposures as long as 17 h. Proteinuria and glucosuria were common and nonspecific postoperative findings. Long-duration low-flow sevoflurane seems as safe as long-duration low-flow isoflurane anesthesia.

IMPLICATIONS: Postoperative renal function after long-duration low-flow sevoflurane (with Compound A exposures greater than those typically reported) and isoflurane anesthesia were not different, as assessed by serum creatinine, blood urea nitrogen, and urinary excretion of protein and glucose. This suggests that low-flow sevoflurane is as safe as low-flow isoflurane, even at long exposures.




This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
J. Stachnik
Inhaled anesthetic agents
Am. J. Health Syst. Pharm., April 1, 2006; 63(7): 623 - 634.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
E. D. Kharasch, J. L. Schroeder, T. Bammler, R. Beyer, and S. Srinouanprachanh
Gene Expression Profiling of Nephrotoxicity from the Sevoflurane Degradation Product Fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl Ether ("Compound A") in Rats
Toxicol. Sci., April 1, 2006; 90(2): 419 - 431.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
T. Nishiyama, T. Fujimoto, and K. Hanaoka
A Comparison of Liver Function After Hepatectomy in Cirrhotic Patients Between Sevoflurane and Isoflurane in Anesthesia with Nitrous Oxide and Epidural Block
Anesth. Analg., April 1, 2004; 98(4): 990 - 993.
[Abstract] [Full Text] [PDF]




Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2001 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2001 by the International Anesthesia Research Society.